A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs TD 8954 (Primary) ; Metoclopramide
- Indications Enteral nutrition dysfunction
- Focus Therapeutic Use
- Sponsors Takeda
- 13 Dec 2018 Status changed from recruiting to discontinued.
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.
- 31 Jul 2018 Status changed to not yet recruiting.